Compare Amgen, Inc. (AMGN) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Yum! Brands, Inc. — how do they compare? Amgen, Inc. trades at $366.95 (market cap $196.12B), while Yum! Brands, Inc. trades at $163.54 (market cap $45.08B). The key difference: Amgen, Inc. is far larger — about 4.4× Yum! Brands, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | YUM | |
|---|---|---|
Market Cap | $196.12B | $45.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $168.16 |
52-Week Low | $271.18 | $138.21 |
Enterprise Value | $241.41B | $56.34B |
Dividend Yield | 2.77% | 1.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
YUM trades at $163.54, up 0.71% with bullish technical signals and strong support at $158. Revenue grew to $8.21B in 2025 with a 20.48% net margin, though profit margins have slightly declined. The recent $2.7B Pizza Hut sale and $4B buyback authorization highlight strategic focus on KFC and Taco Bell growth. Cash flow from operations remains robust at $2.01B, supporting dividend payments and debt management.
Outlook is positive with analyst consensus target of $174 offering 6.4% upside, but high debt levels and competitive pressures pose risks. The stock's valuation at 26.38 P/E requires sustained earnings growth to justify further gains, making execution on digital initiatives and international expansion critical near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
